Kimia Biosciences Limited (BOM:530313)
India
· Delayed Price · Currency is INR 30.15
-0.11 (-0.36%)
At close: Mar 9, 2026
Kimia Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,259 | 1,189 | 1,049 | 1,285 | 1,249 | 1,327 | Upgrade
|
| Revenue | 1,259 | 1,189 | 1,049 | 1,285 | 1,249 | 1,327 | Upgrade
|
| Revenue Growth (YoY) | 13.47% | 13.39% | -18.39% | 2.89% | -5.89% | 24.86% | Upgrade
|
| Cost of Revenue | 788.66 | 722.18 | 765.16 | 977.05 | 934.67 | 979.44 | Upgrade
|
| Gross Profit | 470.62 | 467.03 | 283.6 | 308.11 | 314.34 | 347.7 | Upgrade
|
| Selling, General & Admin | 136.7 | 149.86 | 167.71 | 181.01 | 158.49 | 154.72 | Upgrade
|
| Other Operating Expenses | 136.1 | 114.68 | 112.6 | 156.53 | 149.35 | 109.2 | Upgrade
|
| Operating Expenses | 309.17 | 298.32 | 313.23 | 370.86 | 337.25 | 283.02 | Upgrade
|
| Operating Income | 161.45 | 168.71 | -29.63 | -62.75 | -22.91 | 64.68 | Upgrade
|
| Interest Expense | -31.4 | -35.33 | -44.46 | -37.41 | -31.01 | -24.79 | Upgrade
|
| Interest & Investment Income | 0.22 | 0.22 | 0.37 | 0.29 | 0.31 | 0.54 | Upgrade
|
| Currency Exchange Gain (Loss) | 5.89 | 5.89 | -0.75 | -14.54 | 2.41 | 13.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.78 | -3.15 | -0.99 | 0.25 | 0.21 | 1.02 | Upgrade
|
| EBT Excluding Unusual Items | 130.38 | 136.34 | -75.46 | -114.16 | -50.99 | 54.55 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0 | 0.03 | 0.02 | 0.41 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.79 | 0.37 | Upgrade
|
| Other Unusual Items | - | - | 3.62 | -9.75 | - | 0.02 | Upgrade
|
| Pretax Income | 130.38 | 136.34 | -71.84 | -123.88 | -50.18 | 55.34 | Upgrade
|
| Income Tax Expense | 39.85 | 40.22 | -18.75 | -30.36 | -13.15 | 4.3 | Upgrade
|
| Net Income | 90.52 | 96.12 | -53.09 | -93.52 | -37.03 | 51.04 | Upgrade
|
| Net Income to Common | 90.52 | 96.12 | -53.09 | -93.52 | -37.03 | 51.04 | Upgrade
|
| Net Income Growth | -3.86% | - | - | - | - | 269.56% | Upgrade
|
| Shares Outstanding (Basic) | 47 | 47 | 47 | 47 | 47 | 47 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 47 | 47 | 47 | 47 | 47 | Upgrade
|
| Shares Change (YoY) | 0.13% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 1.91 | 2.03 | -1.12 | -1.98 | -0.78 | 1.08 | Upgrade
|
| EPS (Diluted) | 1.91 | 2.03 | -1.12 | -1.98 | -0.78 | 1.08 | Upgrade
|
| EPS Growth | -4.07% | - | - | - | - | 280.93% | Upgrade
|
| Free Cash Flow | - | 167.15 | 130.28 | -95.82 | 44.17 | -75.94 | Upgrade
|
| Free Cash Flow Per Share | - | 3.53 | 2.75 | -2.02 | 0.93 | -1.60 | Upgrade
|
| Gross Margin | 37.37% | 39.27% | 27.04% | 23.97% | 25.17% | 26.20% | Upgrade
|
| Operating Margin | 12.82% | 14.19% | -2.83% | -4.88% | -1.83% | 4.87% | Upgrade
|
| Profit Margin | 7.19% | 8.08% | -5.06% | -7.28% | -2.96% | 3.85% | Upgrade
|
| Free Cash Flow Margin | - | 14.06% | 12.42% | -7.46% | 3.54% | -5.72% | Upgrade
|
| EBITDA | 193.44 | 200.85 | 2.72 | -30.03 | 6.05 | 83.29 | Upgrade
|
| EBITDA Margin | 15.36% | 16.89% | 0.26% | -2.34% | 0.48% | 6.28% | Upgrade
|
| D&A For EBITDA | 31.99 | 32.14 | 32.35 | 32.73 | 28.96 | 18.61 | Upgrade
|
| EBIT | 161.45 | 168.71 | -29.63 | -62.75 | -22.91 | 64.68 | Upgrade
|
| EBIT Margin | 12.82% | 14.19% | -2.83% | -4.88% | -1.83% | 4.87% | Upgrade
|
| Effective Tax Rate | 30.57% | 29.50% | - | - | - | 7.77% | Upgrade
|
| Revenue as Reported | 1,270 | 1,202 | 1,065 | 1,297 | 1,258 | 1,352 | Upgrade
|
| Advertising Expenses | - | 9.62 | 12.43 | 14.13 | 5.29 | 11.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.